Log in | Register

Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewOpen access

Yara Backes| Koenraad F. van der Sluijs| David P. Mackie| Frank Tacke| Alexander Koch| Jyrki J. Tenhunen| Marcus J. Schultz
Review
Volume 38, Issue 9 / September , 2012

Pages 1418 - 1428

Abstract

Purpose

Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR) positively correlate with the activation level of the immune system. We reviewed the usefulness of systemic levels of suPAR in the care of critically ill patients with sepsis, SIRS, and bacteremia, focusing on its diagnostic and prognostic value.

Methods

A PubMed search on suPAR was conducted, including manual cross-referencing. The list of papers was narrowed to original studies of critically ill patients. Ten papers on original studies of critically ill patients were identified that report on suPAR in sepsis, SIRS, or bacteremia.

Results

Systematic levels of suPAR have little diagnostic value in critically ill patients with sepsis, SIRS, or bacteremia. Systemic levels of suPAR, however, have superior prognostic power over other commonly used biological markers in these patients. Mortality prediction by other biological markers or severity-of-disease classification system scores improves when combining them with suPAR. Systemic levels of suPAR correlate positively with markers of organ dysfunction and severity-of-disease classification system scores. Finally, systemic levels of suPAR remain elevated for prolonged periods after admission and only tend to decline after several weeks. Notably, the type of assay used to measure suPAR as well as the age of the patients and underlying disease affect systemic levels of suPAR.

Conclusions

The diagnostic value of suPAR is low in patients with sepsis. Systemic levels of suPAR have prognostic value, and may add to prognostication of patients with sepsis or SIRS complementing severity-of-disease classification systems and other biological markers.

Keywords

References

  1. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868–1876
    • View reference on PubMed
  2. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58:1843–1849
    • View reference on PubMed
  3. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H (2004) Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr 35:337–342
    • View reference on PubMed
    • View reference on publisher's website
  4. Perch M, Kofoed P, Fischer TK, Có F, Rombo L, Aaby P, Eugen-Olsen J (2004) Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 26:207–211
    • View reference on PubMed
    • View reference on publisher's website
  5. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA (2005) Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 191:1331–1341
    • View reference on PubMed
    • View reference on publisher's website
  6. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I (2002) The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6:686–692
    • View reference on PubMed
  7. Ostrowski SR, Ravn P, Hoyer-Hansen G, Ullum H, Andersen AB (2006) Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy. Scand J Infect Dis 38:1028–1032
    • View reference on PubMed
    • View reference on publisher's website
  8. Garcia-Monco JC, Coleman JL, Benach JL (2002) Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 129:216–223
    • View reference on PubMed
    • View reference on publisher's website
  9. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW (1999) Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 58:488–492
    • View reference on PubMed
    • View reference on publisher's website
  10. Pliyev BK, Menshikov MY (2010) Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 33:1–9
    • View reference on PubMed
    • View reference on publisher's website
  11. Andersen ES, Ruhwald M, Moessner B, Christensen PB, Andersen O, Eugen-Olsen J, Weis N (2011) Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis 30:761–766
    • View reference on PubMed
    • View reference on publisher's website
  12. Lonnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM (2011) Blood chemistry markers for evaluation of inflammatory activity in Crohn’s disease during infliximab therapy. Scand J Gastroenterol 46:420–427
    • View reference on PubMed
    • View reference on publisher's website
  13. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91:869–874
    • View reference on PubMed
    • View reference on publisher's website
  14. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW (1999) The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 107:160–167
    • View reference on PubMed
    • View reference on publisher's website
  15. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J (2000) Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96:4091–4095
    • View reference on PubMed
  16. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H (2005) High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 39:23–31
    • View reference on PubMed
    • View reference on publisher's website
  17. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF 3rd (1995) Enzyme-linked immuno-absorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 86:203–211
    • View reference on PubMed
  18. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, Standards for Reporting of Diagnostic Accuracy (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1–6
    • View reference on PubMed
    • View reference on publisher's website
  19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7–18
    • View reference on PubMed
    • View reference on publisher's website
  20. Molkanen T, Ruotsalainen E, Thorball CW, Järvinen A (2011) Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 30:1417–1424
    • View reference on PubMed
    • View reference on publisher's website
  21. Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G (2006) Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 34:2561–2566
    • View reference on PubMed
    • View reference on publisher's website
  22. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K (2007) Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 11:R38
    • View reference on PubMed
    • View reference on publisher's website
  23. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O (2008) Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 27:375–383
    • View reference on PubMed
    • View reference on publisher's website
  24. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J (2006) Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 52:1284–1293
    • View reference on PubMed
    • View reference on publisher's website
  25. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15:R63
    • View reference on PubMed
    • View reference on publisher's website
  26. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J (2004) The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 10:409–415
    • View reference on PubMed
    • View reference on publisher's website
  27. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270:32–40
    • View reference on PubMed
    • View reference on publisher's website
  28. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, van der Poll T (2001) Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 59:2054–2061
    • View reference on PubMed
  29. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, ACCP/SCCM Consensus Conference Committee (2009) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine 1992. Chest 136(5 suppl):e28
    • View reference on PubMed
    • View reference on publisher's website
  30. Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15
    • View reference on PubMed
    • View reference on publisher's website
  31. Christ-Crain M, Muller B (2007) Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 30:556–573
    • View reference on PubMed
    • View reference on publisher's website
  32. Kibe S, Adams K, Barlow G (2011) Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 66(Suppl 2):ii33–ii40
    • View reference on PubMed
    • View reference on publisher's website
  33. Standage SW, Wong HR (2011) Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 9:71–79
    • View reference on PubMed
    • View reference on publisher's website
  34. Becker KL, Snider R, Nylen ES (2008) Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 36:941–952
    • View reference on PubMed
    • View reference on publisher's website
  35. Schuetz P, Christ-Crain M, Muller B (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—hope for hype? Swiss Med Wkly 139:318–326
    • View reference on PubMed
  36. Sier CF, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F (1999) Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 79:717–722
    • View reference on PubMed
  37. Thuno M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27:157–172
    • View reference on PubMed
  38. Ossowski L, Aguirre-Ghiso JA (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12:613–620
    • View reference on PubMed
    • View reference on publisher's website
  39. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15:1572–1582
    • View reference on PubMed
  40. Mondino A, Blasi F (2004) uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25:450–455
    • View reference on PubMed
    • View reference on publisher's website
  41. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T (2002) Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 168:3507–3511
    • View reference on PubMed
  42. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P (2005) Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105:2198–2205
    • View reference on PubMed
    • View reference on publisher's website
  43. Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E (2009) Participation of the urokinase receptor in neutrophil efferocytosis. Blood 114:860–870
    • View reference on PubMed
    • View reference on publisher's website
  44. Wiersinga WJ, Kager LM, Hovius JW, van der Windt GJ, de Vos AF, Meijers JC, Roelofs JJ, Dondorp A, Levi M, Day NP, Peacock SJ, van der Poll T (2010) Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 184:3079–3086
    • View reference on PubMed
    • View reference on publisher's website
  45. McMaken S, Exline MC, Mehta P, Piper M, Wang Y, Fischer SN, Newland CA, Schrader CA, Balser SR, Sarkar A, Baran CP, Marsh CB, Cook CH, Phillips GS, Ali NA (2011) Thrombospondin-1 contributes to mortality in murine sepsis through effects on innate immunity. PLoS ONE 6:e19654
    • View reference on PubMed
    • View reference on publisher's website
  46. Quach S, Hennessy DA, Faris P, Fong A, Quan H, Doig C (2009) A comparison between the APACHE II and Charlson index score for predicting hospital mortality in critically ill patients. BMC Health Serv Res 9:129
    • View reference on PubMed
    • View reference on publisher's website
  47. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
    • View reference on PubMed
    • View reference on publisher's website
  48. Mirsaeidi M, Peyrani P, Ramirez JA, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators (2009) Predicting mortality in patients with ventilator-associated pneumonia: the APACHE II score versus the new IBMP-10 score. Clin Infect Dis 49:72–77
    • View reference on PubMed
    • View reference on publisher's website
  49. Riisbro R, Christensen IJ, Hogdall C, Brünner N, Høgdall E (2001) Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 16:233–239
    • View reference on PubMed
  50. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596
    • View reference on PubMed
    • View reference on publisher's website
  51. Moran JL, Bristow P, Solomon PJ, George C, Hart GK, Australian and New Zealand Intensive Care Society Database Management Committee (ADMC) (2008) Mortality and length-of-stay outcomes, 1993–2003, in the binational Australian and New Zealand intensive care adult patient database. Crit Care Med 36:46–61
    • View reference on PubMed
    • View reference on publisher's website
  52. Kaufmann PA, Smolle KH, Krejs GJ (2009) Short- and long-term survival of nonsurgical intensive care patients and its relation to diagnosis, severity of disease, age and comorbidities. Curr Aging Sci 2:240–248
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement